Market Closed - Nyse 01:40:00 29/05/2024 am IST 5-day change 1st Jan Change
0.6019 USD -3.70% Intraday chart for Know Labs, Inc. -9.62% +18.25%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Know Labs, Inc. Announces the Appointment of Chris Somogyi as President, International CI
Transcript : Know Labs, Inc., Q2 2024 Earnings Call, May 15, 2024
Know Labs, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024 CI
Know Labs, Inc. to Present Clinical Research At the 2024 American Association of Clinical Endocrinology Annual Meeting CI
Certain Common Stock of Know Labs, Inc. are subject to a Lock-Up Agreement Ending on 27-MAR-2024. CI
Know Labs, Inc. Announces Interim Results from its Most Recent Clinical Research Study CI
Know Labs, Inc. announced that it expects to receive $12 million in funding from The Lind Partners, LLC CI
Transcript : Know Labs, Inc., Q1 2024 Earnings Call, Feb 14, 2024
Know Labs, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023 CI
Know Labs, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023 CI
Transcript : Know Labs, Inc., Q4 2023 Earnings Call, Dec 19, 2023
Know Labs, Inc. Announces Board Appointments CI
Know Labs, Inc. Expands Board of Directors CI
Transcript : Know Labs, Inc., Q3 2024 Earnings Call, Aug 14, 2023
Know Labs, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023 CI
Know Labs, Inc. Demonstrates Improved Accuracy of Machine Learning Model for Non-Invasive Glucose Monitor CI
Know Labs Completes Build of Portable Generation 1 Prototype for Non-Invasive Glucose Monitoring CI
Know Labs, Inc. Furthers External Validation of Bio-RFID(TM) Technology with Study Published in Sensors Journal CI
Know Labs, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023 CI
Know Labs, Inc. Study Validates Technical Feasibility of Its Novel Sensor for Non-Invasive Glucose Monitoring CI
Know Labs, Inc. Announces Board Appointments CI
Certain Warrants of Know Labs, Inc. are subject to a Lock-Up Agreement Ending on 21-MAR-2023. CI
Certain Convertible Debentures of Know Labs, Inc. are subject to a Lock-Up Agreement Ending on 21-MAR-2023. CI
Certain Series D Convertible Preferred Stock of Know Labs, Inc. are subject to a Lock-Up Agreement Ending on 21-MAR-2023. CI
Certain Series C Convertible Preferred Stock of Know Labs, Inc. are subject to a Lock-Up Agreement Ending on 21-MAR-2023. CI
Chart Know Labs, Inc.
More charts
Know Labs, Inc. is a provider of non-invasive blood glucose monitoring solutions. The Company is focused on the development and commercialization of its proprietary sensor technology utilizing radio and microwave spectroscopy. When paired with its machine learning platform, the Company’s Bio-RFID sensor technology platform identifies and measures various material or analyte using electromagnetic energy to detect, record, identify and measure the signature of said materials or analytes. The data obtained with its sensor technology is analyzed with the Company’s trade secret algorithms. The Company is focused on analytes relating to human health, the identification, of which provide diagnostic information and require, by their nature, clearance by the United States Food and Drug Administration. The first among those analytes is the non-invasive monitoring of blood glucose levels. Its device provides the user with real-time information on their blood glucose levels.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.6019 USD
Average target price
1 USD
Spread / Average Target
+66.14%
Consensus